astrazeneca

Latest stories

  • in Health care

    AstraZeneca, Sanofi, Sobi simplify contractual agreements for Nirsevimab

    AstraZeneca, Sanofi, Sobi simplify contractual agreements for Nirsevimab

    by

    Paris. Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.). Under the new and updated arrangements, Sobi will terminate its participation agreement with AstraZeneca, and Sanofi and AstraZeneca will update the Collaboration Agreement so that Sanofi has full commercial control of nirsevimab in the […] More

  • in Health care

    AstraZeneca announces positive results from ovarian cancer combo therapy trial

    AstraZeneca announces positive results from ovarian cancer combo therapy trial

    by

    UK: AstraZeneca has announced positive high-level results from a planned interim analysis of the DUO-O Phase III trial. The results showed treatment with a combination of Lynparza (olaparib), Imfinzi (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus chemotherapy plus bevacizumab (control arm) in newly diagnosed patients […] More

  • in Health care

    AstraZeneca Ultomiris recommended for marketing approval in EU for neuromyelitis optica spectrum disorder

    by

    UK: AstraZeneca has announced that Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). If authorised, Ultomiris would be the first and only approved long-acting C5 complement inhibitor for the treatment of AQP4 […] More

  • in Health care

    All SAEs including death should be reported: CDSCO Panel tells AstraZeneca about Durvalumab

    by

    New Delhi: Granting the protocol amendment proposal presented by drug major AstraZeneca for anticancer drug Durvalumab, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has stated that all serious adverse events (SAEs) including death irrespective of its cause should be reported to CDSCO as per provision of New Drugs […] More